
Nephros Inc
NASDAQ:NEPH

Intrinsic Value
The intrinsic value of one
NEPH
stock under the Base Case scenario is
0.9742
USD.
Compared to the current market price of 2.6299 USD,
Nephros Inc
is
Overvalued by 63%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Nephros Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Nephros Inc
Balance Sheet Decomposition
Nephros Inc
Current Assets | 9m |
Cash & Short-Term Investments | 4.1m |
Receivables | 2.7m |
Other Current Assets | 2.2m |
Non-Current Assets | 2.8m |
PP&E | 1.4m |
Intangibles | 1.3m |
Other Non-Current Assets | 50k |
Free Cash Flow Analysis
Nephros Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Nephros Inc
Revenue
|
15.5m
USD
|
Cost of Revenue
|
-5.8m
USD
|
Gross Profit
|
9.7m
USD
|
Operating Expenses
|
-8.9m
USD
|
Operating Income
|
772k
USD
|
Other Expenses
|
29k
USD
|
Net Income
|
801k
USD
|
NEPH Profitability Score
Profitability Due Diligence
Nephros Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Score
Nephros Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
NEPH Solvency Score
Solvency Due Diligence
Nephros Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Score
Nephros Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEPH Price Targets Summary
Nephros Inc
According to Wall Street analysts, the average 1-year price target for
NEPH
is 4.59 USD
with a low forecast of 4.545 USD and a high forecast of 4.725 USD.
Dividends
Current shareholder yield for NEPH is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NEPH
stock under the Base Case scenario is
0.9742
USD.
Compared to the current market price of 2.6299 USD,
Nephros Inc
is
Overvalued by 63%.